See more : AB Electrolux (publ) (ELUX-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Trean Insurance Group, Inc. (TIG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trean Insurance Group, Inc., a leading company in the Insurance – Specialty industry within the Financial Services sector.
You may be interested
- Forte Biosciences, Inc. (FBRX) Income Statement Analysis – Financial Results
- General Elevator Co., Ltd (300931.SZ) Income Statement Analysis – Financial Results
- Katsuragawa Electric Co., Ltd. (6416.T) Income Statement Analysis – Financial Results
- Obsidian Energy Ltd. (OBELF) Income Statement Analysis – Financial Results
- Rana Gruber ASA (RANA.OL) Income Statement Analysis – Financial Results
Trean Insurance Group, Inc. (TIG)
About Trean Insurance Group, Inc.
Trean Insurance Group, Inc. underwrites specialty casualty insurance products in the United States. The company underwrites business, predominantly workers' compensation, accident and health, and medical professional liability products. It also offers a variety of services, including issuing carrier, claims administration, and reinsurance brokerage services. The company offers its products through program partners and managing general agents. Trean Insurance Group, Inc. was founded in 1996 and is based in Wayzata, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12.02M | 219.92M | 132.26M | 102.52M | 78.50M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.02M | 219.92M | 132.26M | 102.52M | 78.50M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 52.81M | 50.22M | 39.17M | 21.01M | 15.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -27.00K |
| SG&A | 52.81M | 50.22M | 39.17M | 21.01M | 15.68M |
| Other Expenses | 294.04M | -245.36M | -85.94M | -85.16M | -16.32M |
| Operating Expenses | 380.25M | -195.14M | -46.77M | -64.16M | -639.00K |
| Cost & Expenses | 380.15M | 195.14M | 37.00M | 67.71M | 52.35M |
| Interest Income | 192.00K | 4.00K | 25.00K | 127.00K | 90.00K |
| Interest Expense | 3.27M | 1.69M | 1.92M | 2.17M | 1.56M |
| Depreciation & Amortization | 6.00M | 5.83M | 2.57M | 876.00K | 497.00K |
| EBITDA | -54.79M | 30.61M | 88.06M | 39.24M | 27.12M |
| EBITDA Ratio | -455.70% | 13.92% | 66.58% | 38.27% | 34.55% |
| Operating Income | -60.79M | 24.78M | 85.49M | 38.36M | 26.63M |
| Operating Income Ratio | -505.58% | 11.27% | 64.64% | 37.42% | 33.92% |
| Total Other Income/Expenses | -4.09M | 0.00 | 9.77M | -46.71M | -475.00K |
| Income Before Tax | -64.88M | 24.78M | 95.26M | 34.80M | 26.15M |
| Income Before Tax Ratio | -539.60% | 11.27% | 72.03% | 33.95% | 33.31% |
| Income Tax Expense | 1.07M | 5.45M | 6.83M | 7.07M | 5.55M |
| Net Income | -65.96M | 19.33M | 90.77M | 31.29M | 19.52M |
| Net Income Ratio | -548.53% | 8.79% | 68.63% | 30.52% | 24.87% |
| EPS | -1.29 | 0.38 | 2.02 | 0.75 | 0.38 |
| EPS Diluted | -1.29 | 0.38 | 2.02 | 0.75 | 0.38 |
| Weighted Avg Shares Out | 51.20M | 51.16M | 43.74M | 37.39M | 51.14M |
| Weighted Avg Shares Out (Dil) | 51.20M | 51.17M | 43.74M | 37.39M | 51.14M |
Takeda publie des informations concernant son offre publique d’acquisition volontaire et conditionnelle des actions, des bons de souscription et des actions américaines de dépôt en circulation de TiGenix
OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (« Takeda ») a annoncé aujourd’hui des informations relatives à son offre publique d’achat en numéraire annoncée et en cours (l’« Offre ») pour toutes les actions ordinaires en circulation (les «...
Takeda anuncia una oferta pública de adquisición voluntaria y condicional para las acciones en circulación, las autorizaciones de adquisición y las acciones de depósito estadounidenses de TiGenix NV, que comenzará el 30 de abril de 2018
OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) ha anunciado hoy que el primer periodo de aceptación de su oferta pública de adquisición previamente anunciada (la “Oferta”) en efectivo para todas las acciones en circulación ordinarias (“Acciones ordinarias”), autorizaciones...
Takeda kondigt start Vrijwillige en Voorwaardelijke Openbare Overnamebod aan voor uitstaande aandelen, warrants en American Depositary Shares van TiGenix NV op 30 april 2018
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) kondigt vandaag aan dat de eerste aanvaardingsperiode van haar eerder aangekondigde overnamebod (het “Bod”) in cash voor alle uitstaande gewone aandelen (“Gewone aandelen”), warrants (“Warrants”) en Amerikaanse Depositary Shares (“ADS”) van...
Takeda annonce que l’offre publique d’acquisition volontaire et conditionnelle des actions, des warrants et des ADSs (American Depositary Shares, actions détenues par des détenteurs qui résident aux USA) en circulation de TiGenix NV ...
OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE : 4502): Takeda annonce que l’offre publique d’acquisition volontaire et conditionnelle des actions, des warrants et des ADSs (American Depositary Shares, actions détenues par des détenteurs qui résident aux USA) en circulation de...
Takeda Announces Voluntary and Conditional Public Takeover Bid for Outstanding Shares, Warrants and American Depositary Shares of TiGenix NV to Commence April 30, 2018
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the first acceptance period of its previously announced tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”)...
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
OSAKA, Japan & LEUVEN, Belgium--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in...
Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601
OSAKA, Japan & LEUVEN, Belgium--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq:TIG) (“TiGenix”) today announced new data from the Phase 3 ADMIRE-CD clinical trial, which indicated that investigational compound Cx601, a suspension of allogeneic...
Form 8.5 - INNOVATION GROUP PLC
LONDON--(BUSINESS WIRE)-- FORM 8.5 (EPT/NON-RI) PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (“RI”) STATUS (OR WHERE RI STATUS IS NOT APPLICABLE) Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION BARCLAYS CAPITAL...
Form 8.5 (EPT/NON-RI) - INNOVATION GROUP PLC
LONDON--(BUSINESS WIRE)-- FORM 8.5 (EPT/NON-RI) PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (“RI”) STATUS (OR WHERE RI STATUS IS NOT APPLICABLE) Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION 2. POSITIONS...
Form 8.5 (EPT/NON-RI) - INNOVATION GROUP PLC
LONDON--(BUSINESS WIRE)-- FORM 8.5 (EPT/NON-RI) PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (“RI”) STATUS (OR WHERE RI STATUS IS NOT APPLICABLE) Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION 2. POSITIONS...
Source: https://incomestatements.info
Category: Stock Reports